Results 91 to 100 of about 345,855 (252)

Validating the pivotal role of the immune system in low‐dose radiation‐induced tumor inhibition in Lewis lung cancer‐bearing mice

Cancer Medicine, 2018
Although low‐dose radiation (LDR) possesses the two distinct functions of inducing hormesis and adaptive responses, which result in immune enhancement and tumor inhibition, its clinical applications have not yet been elucidated.
Lei Zhou, Xiaoying Zhang, Hui Li, Chao Niu, Dehai Yu, Guozi Yang, Xinyue Liang, Xue Wen, Min Li, Jiuwei Cui   +9 more
doaj   +1 more source

Monte Carlo simulation of physical dose enhancement in core-shell magnetic gold nanoparticles with TOPAS. [PDF]

Front Oncol, 2022
Xu X, Wu J, Dai Z, Hu R, Xie Y, Wang L.
europepmc   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Quantification of Nanoscale Dose Enhancement in Gold Nanoparticle-Aided External Photon Beam Radiotherapy. [PDF]

Cancers (Basel), 2022
Vlastou E, Pantelis E, Efstathopoulos EP, Karaiskos P, Kouloulias V, Platoni K.   +5 more
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Impact of the Spectral Composition of Kilovoltage X-rays on High-Z Nanoparticle-Assisted Dose Enhancement. [PDF]

Int J Mol Sci, 2021
Kolyvanova MA, Belousov AV, Krusanov GA, Isagulieva AK, Morozov KV, Kartseva ME, Salpagarov MH, Krivoshapkin PV, Dement'eva OV, Rudoy VM, Morozov VN.   +10 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

On the importance of modeling gold nanoparticles distribution in dose-enhanced radiotherapy

International Journal of Nanomedicine, 2019
Fatemeh S Rasouli,1 S Farhad Masoudi,1 Somayeh Asadi21Department of Physics, K.N. Toosi University of Technology, Tehran, Iran; 2Department of Mechanical Engineering, Politecnico Di Milano, Milan, ItalyPurpose: To investigate the effect of precise ...
Rasouli FS, Masoudi SF, Asadi S
doaj  

Combined cell and nanoparticle models for TOPAS to study radiation dose enhancement in cell organelles. [PDF]

Sci Rep, 2021
Hahn MB, Zutta Villate JM.
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source